ABSTRACT
COVID-19, an extremely contagious disease is showing high rate of infection and fatality, posing a major problem to the population. COVID-19 develops hypoxic respiratory failure. COVID and ARDS both lead to failure of multiple organs. According to WHO, as of 10 June 2022, 532,201,219 confirmed cases of COVID-19 and 6,305,358 deaths have been reported globally. Primary available protection against this SARS-CoV-2 is population-based vaccination which has reduced the infection risk. Yet, SARS-CoV-2 virus continues to be a mystery, as many aspects such as transmission, infection and therapy, are still being studied. Various mutations have been incurred in the Coronavirus due to which potential efficacy of COVID vaccines has reduced. Therefore, the development of supplementary antiCovid19 strategy is still a top priority globally. As a new emergent therapeutic method for COVID-19, stem cell therapy and its derived organoid models have attracted a lot of attention. Stem cells, specifically mesenchymal stem cells (MSCs), have potent tissue healing, anti-inflammatory and immunomodulatory characteristics that might be used to treat COVID-19 patients with damaged organs like lungs and ARDS and compromised immune system. In present review, we have discussed rationality of MSC treatment for COVID-19 as well as the prospects and challenges of utilizing MSCs as a treatment approach in COVID-19. © 2023 World Research Association. All rights reserved.
ABSTRACT
COVID-19, an extremely contagious disease is showing high rate of infection and fatality, posing a major problem to the population. COVID-19 develops hypoxic respiratory failure. COVID and ARDS both lead to failure of multiple organs. According to WHO, as of 10 June 2022, 532,201,219 confirmed cases of COVID-19 and 6,305,358 deaths have been reported globally. Primary available protection against this SARS-CoV-2 is population-based vaccination which has reduced the infection risk. Yet, SARS-CoV-2 virus continues to be a mystery, as many aspects such as transmission, infection and therapy, are still being studied. Various mutations have been incurred in the Coronavirus due to which potential efficacy of COVID vaccines has reduced. Therefore, the development of supplementary antiCovid19 strategy is still a top priority globally. As a new emergent therapeutic method for COVID-19, stem cell therapy and its derived organoid models have attracted a lot of attention. Stem cells, specifically mesenchymal stem cells (MSCs), have potent tissue healing, anti-inflammatory and immunomodulatory characteristics that might be used to treat COVID-19 patients with damaged organs like lungs and ARDS and compromised immune system. In present review, we have discussed rationality of MSC treatment for COVID-19 as well as the prospects and challenges of utilizing MSCs as a treatment approach in COVID-19.
ABSTRACT
The coronavirus disease 2019 (COVID-19), elicited by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, is a pandemic public health emergency of global concern. Other than the profound severe pulmonary damage, SARS-CoV-2 infection also leads to a series of cardiovascular abnormalities, including myocardial injury, myocarditis and pericarditis, arrhythmia and cardiac arrest, cardiomyopathy, heart failure, cardiogenic shock, and coagulation abnormalities. mechanisms have been postulated for COVID-19-associated cardiovascular damage including SARS-CoV-2 receptor angiotensin-converting enzyme 2 (ACE2) activation, cytokine storm, hypoxemia, stress and cardiotoxicity of antiviral drugs. In this paper we reported a patient with severe Cocid 19 pnumonia that had very high level of Troponin I without history of cardio vascular and other underlying diseases expect mild HTN with use of amlodipine. She had a ECG with old LBBB without significant ST-T bnormality and normal data in Trance thoracic echocardiography(TTE). We named this condition subclinical involvemet of cardiovascular system in Covid19 and our discussion is about reasons and origination of this Troponin elevation.
ABSTRACT
With the coronavirus disease 2019 (COVID-19) pandemic in the United States, a majority of states have instituted "shelter-in-place" policies effectively quarantining individuals-including pregnant persons-in their homes. Given the concern for COVID-19 acquisition in health care settings, pregnant persons with high-risk pregnancies-such as persons living with HIV (PLHIV)-are increasingly investigating the option of a home birth. Although we strongly recommend hospital birth for PLHIV, we discuss our experience and recommendations for counseling and preparation of pregnant PLHIV who may be considering home birth or at risk for unintentional home birth due to the pandemic. We also discuss issues associated with implementing a risk mitigation strategy involving high-risk births occurring at home during a pandemic. KEY POINTS: · Coronavirus disease 2019 pandemic has increased interest in home birth.. · Women living with HIV are pursuing home birth.. · Safe planning is paramount for women living with HIV desiring home birth, despite recommending against the practice..